CORDIS Project

Neurotoxicity De-Risking in Preclinical Drug Discovery

NeuroDeRisk·821528·H2020

Funding breakdown and partner intelligence are Premium

Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1

Upgrade

Start free • Cancel anytime • 14-day refund guarantee

View on CORDIS DOI grant

Funding data

Programme: Horizon 2020
Participants: 4
Start - End: 01/03/2019 — 30/09/2022
Status: CLOSED

Summary

NeuroDeRisk aims to enhance the predictability of preclinical studies for drug safety by addressing neurotoxic effects. The project combines expertise in neurobiology and software development to create innovative tools for better risk assessment in drug development.

Objective

The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process.

Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition).

By combining top level scientists in neurobiology/toxicology with successful software de…

Full objective and premium intelligence

Upgrade to Premium for the complete objective, AI summary, similar projects, consortium analytics, OpenAlex context, and funding breakdown.

Upgrade Sign in

Start free • Cancel anytime • 14-day refund guarantee

Coordinator

UNIVIE

UNIVERSITAT WIEN

Country: Austria, Wien
Organization type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No

Network and participants(4 participants)

Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.

MEDIZINISCHE UNIVERSITAET WIEN
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
participant
FACULTY OF PHARMACY UNIVERSITY OF BELGRADE
Serbia, BELGRADE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
participant
INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH
Austria, Maria Enzersdorf
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
participant
UNIVERSITY OF EASTERN FINLAND (UEF)
Finland, KUOPIO
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
participant

4 participants shown of 18

Upgrade Sign in

Start free • Cancel anytime • 14-day refund guarantee

Partner & research intelligence

Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.

Consortium analytics and research context are Premium

Upgrade Sign in

Start free • Cancel anytime • 14-day refund guarantee

CORDIS call / funding scheme

Programme: H2020
Call: H2020-JTI-IMI2-2017-13-two-stage
Sub call: H2020-JTI-IMI2-2017-13-two-stage
Funding scheme: RIA - Research and Innovation action
Domain note: This block describes the CORDIS project call context. Live open opportunities are managed in the Funding & Tenders domain.

Fields of Science (EuroSciVoc)

Guests see up to 5 EuroSciVoc fields.

Medical and health sciencesBasic medicinePharmacology and pharmacyDrug discovery
Medical and health sciencesBasic medicinePharmacology and pharmacyPharmaceutical drugs
Medical and health sciencesBasic medicinePharmacology and pharmacyPharmacokinetics
Medical and health sciencesBasic medicineToxicology
Medical and health sciencesMedical biotechnologyCells technologiesStem cells

Topic

Guests see up to 5 topics.

IMI2-2017-13-10

Keywords

Guests see up to 5 keywords.

Neurotoxicty Prediction